Precigen, Inc.

Healthcare · Biotechnology · United States

Last price 6.94 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 2.48B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients. It also develops pro...